{
    "clinical_study": {
        "@rank": "104282", 
        "arm_group": {
            "arm_group_label": "ATRA-Idarubicin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Therapeutic guidelines for treatment of patients with de novo APL to be used by every\n      institution that wants to follow them. All patients who are reported may be retrospectively\n      analyzed"
        }, 
        "brief_title": "Clinical Guidelines for APL Treatment", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "APL", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Genetic diagnosis of acute promyelocytic leukemia\n\n        Exclusion Criteria:\n\n          -  No exclusion criteria"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02020161", 
            "org_study_id": "PETHEMA LPA2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "ATRA-Idarubicin", 
                "intervention_name": "Atra", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ATRA-Idarubicin", 
                "intervention_name": "Idarubicin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ATRA-Idarubicin", 
                "intervention_name": "methotrexate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Idarubicin", 
                "Methotrexate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 23, 2013", 
        "location": {
            "contact": {
                "email": "montesinos_pau@gva.es", 
                "last_name": "Pau Montesinos, Dr"
            }, 
            "facility": {
                "address": {
                    "city": "Valencia", 
                    "country": "Spain"
                }, 
                "name": "Hospital La Fe"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "montesinos_pau@gva.es", 
            "last_name": "Pau Montesinos, Dr", 
            "phone": "+34 96 1244000"
        }, 
        "overall_contact_backup": {
            "email": "martinez_davcua@gva.es", 
            "last_name": "David Martinez, Dr", 
            "phone": "+34 96 1244000."
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Induction therapy with simultaneous ATRA (45 mg/m2 day until CR) and idarubicin (12 mg/m2 day on days 2, 4, 6 and 8 or 12 mg/m2 day on days 2, 4 and 6  in patients older than or equal to 60 years).\nThree monthly consolidation courses with ATRA Maintenance therapy with ATRA (45 mg/m2/d, days 1-15 every 3 months), and low dose chemotherapy with methotrexate (15 mg/m2/d, weekly) and 6-mercaptopurine (50 mg/m2/d) for two years.", 
            "measure": "Recurrence within 1 year of treatment", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02020161"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "PETHEMA Foundation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PETHEMA Foundation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}